U.S. patent application number 17/376484 was filed with the patent office on 2021-11-04 for co-expression of magnetotactic bacterial genes and genes encoding iron handling proteins in cells.
The applicant listed for this patent is MULTI-MAGNETICS INCORPORATED. Invention is credited to Rene FIGUEREDO, Neil GELMAN, Donna E. GOLDHAWK, D. James KOROPATNICK, Frank S. PRATO, R. Terry THOMPSON.
Application Number | 20210338843 17/376484 |
Document ID | / |
Family ID | 1000005720313 |
Filed Date | 2021-11-04 |
United States Patent
Application |
20210338843 |
Kind Code |
A1 |
GOLDHAWK; Donna E. ; et
al. |
November 4, 2021 |
Co-Expression of Magnetotactic Bacterial Genes and Genes Encoding
Iron Handling Proteins in Cells
Abstract
The invention provides an improved modified magnetosome that
contains more iron therein with the combination of the expressed
genes. This is achieved by co-expression of (a) one or more
bacterial magnetotactic genes to amplify iron uptake,
compartmentalization and biomineralization in cells, with (b) one
or more mammalian iron handling proteins that together augment(s)
and/or regulate the cells iron pool. As a result, mammalian cells
or bacterial cells that are transfected or transformed,
respectively, can be more effectively tracked using various imaging
technologies.
Inventors: |
GOLDHAWK; Donna E.; (London,
CA) ; KOROPATNICK; D. James; (London, CA) ;
FIGUEREDO; Rene; (London, CA) ; PRATO; Frank S.;
(London, CA) ; THOMPSON; R. Terry; (London,
CA) ; GELMAN; Neil; (London, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
MULTI-MAGNETICS INCORPORATED |
London |
|
CA |
|
|
Family ID: |
1000005720313 |
Appl. No.: |
17/376484 |
Filed: |
July 15, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15121653 |
Aug 25, 2016 |
11077215 |
|
|
PCT/CA2014/000555 |
Jul 8, 2014 |
|
|
|
17376484 |
|
|
|
|
61944146 |
Feb 25, 2014 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12Q 1/689 20130101;
C12Q 1/6883 20130101; C12N 15/85 20130101; C12N 2510/00 20130101;
C07K 14/195 20130101; A61K 49/1896 20130101 |
International
Class: |
A61K 49/18 20060101
A61K049/18; C12N 15/85 20060101 C12N015/85; C07K 14/195 20060101
C07K014/195; C12Q 1/6883 20060101 C12Q001/6883; C12Q 1/689 20060101
C12Q001/689 |
Claims
1. An expression system for augmenting and/or regulating iron
levels in cells, said expression system comprising (a) one or more
bacterial magnetotactic gene to amplify iron uptake,
compartmentalization and biomineralization in cells, and (b) one or
more genes each encoding one or more eukaryotic ferritin subunits,
the one or more genes lacking an iron responsive element (IRE),
wherein (a) and (b) are under control of one or more promoters and,
optionally, one or more selection markers.
2. The expression system of claim 1 wherein said one or more
eukaryotic ferritin subunits are mammalian.
3. The expression system of claim 1, wherein the one or more
eukaryotic ferritin subunits comprise both a ferritin heavy subunit
and a ferritin light subunit.
4. The expression system of claim 1, wherein said cells are
eukaryotic.
5. A cell transformed with the expression system of claim 1.
6. The cell of claim 5, wherein said cell is detected using an
imaging system selected from the group consisting of positron
emission tomography (PET), magnetic resonance imaging (MRI),
gamma-ray imaging camera (GREI-II), computed tomography (CT),
Single photon emission computed tomography (SPECT), bioluminescence
tomography (BLT), magnetic particle imaging (MPI) and combinations
thereof.
7. A method of augmenting and/or regulating iron levels in cells
and subsequent detection of the cells, the method comprising
utilizing the expression system of claim 1 to co-express said one
or more bacterial magnetotactic genes to form a magnetosome-like
structure containing augmented amounts of iron therein; and
detecting the cells using an imaging system selected from the group
consisting of positron emission tomography (PET), magnetic
resonance imaging (MRI), gamma-ray imaging camera (GREI-H),
computed tomography (CT), Single photon emission computed
tomography (SPECT), bioluminescence tomography (BLT), magnetic
particle imaging (MPI) and combinations thereof.
8. The method of claim 7 for use in one or more of the following:
detecting changes in cellular iron; tracking cancer growth and
metastasis; image, quantify and/or monitor progression of
transplanted stem cells; tracking neurodegenerative disorders; and
cell tracking in vivo.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 15/121,653, filed Aug. 25, 2016, which itself
is a U.S. nationalization under 35 U.S.C. .sctn. 371 of
International Application No. PCT/CA2014/000555, filed Jul. 8,
2014, which claims the benefit of priority under 35 U.S.C. .sctn.
119(e) to U.S. Provisional Application Ser. No. 61/944,146, filed
Feb. 25, 2014. The disclosures set forth in the referenced
applications are incorporated herein by reference in their
entireties, including all information as originally submitted to
the United States Patent and Trademark Office.
FIELD OF INVENTION
[0002] The invention relates to the production of magnetosome-like
structures in cells with increased iron storage. More specifically,
the invention provides gene expression systems using a combination
of magnetotactic bacterial gene(s) with mammalian genes involved in
iron handling in order to augment a cell's iron pool. The invention
further provides in vitro and in vivo imaging, diagnostic and
therapeutic methods using cells co-expressing the resultant
increased iron containing magnetosome-like structures in order to
enhance iron contrast using a variety of imaging technologies.
BACKGROUND OF THE INVENTION
[0003] Non-invasive mapping of cellular or subcellular events in
living organisms, or molecular imaging, is an evolving and largely
unexplored field. Magnetic resonance imaging (MRI) is used for in
vivo cellular imaging and requires the use of cellular contrast
agents. While many of the current developments in contrast agents
continue to revolve around SPIO (superparamagnetic iron oxide)
particles, progress in the field of gene-based contrast is being
recognized (6).
[0004] The bacterial, putative iron transport protein MagA has been
implicated, among other proteins, in the formation of magnetosomes:
membrane-enclosed vesicles that compartmentalize iron biominerals
(1, 2). Magnetosomes are not toxic and impart magnetic properties
to the cell that may be clinically useful (3, 4). Canadian patent
application 2,655,118 (the disclosure of which is hereby
incorporated by reference in its entirety) describes the use of
magnetosome genes in eukaryotic cells, including MagA derived iron
contrast, for cell tracking using MRI.
[0005] There however, remains a need to improve the MR signal for a
variety of clinical diagnostic and therapeutic applications.
SUMMARY OF THE INVENTION
[0006] The present invention provides a gene based iron contrast by
the augmentation of a cell's iron pool. The present invention
combines the use of magnetotactic genes that form magnetosome-like
structures in cells with genes encoding iron handling proteins.
[0007] The invention in its broadest sense is the co-expression of
(a) one or more bacterial magnetotactic genes to amplify iron
uptake, compartmentalization and biomineralization in cells, with
(b) one or more genes encoding iron handling proteins that together
augment(s) and/or regulate the cells' iron pool. The invention
provides an improved modified magnetosome that contains more iron
therein with the combination of the expressed genes. More iron
encompasses the aspect of amount as well as size of the iron
biomineral produced and/or crystal structure all of which
contribute to a better signal for imaging technologies. As a
result, mammalian cells or bacterial cells that are transfected or
transformed, respectively, can be more effectively tracked using
various imaging technologies.
[0008] In a representative but non-limiting embodiment, the
invention provides the co-expression of ferritin subunits (heavy
and/or light chains) with one or more magnetotactic bacterial
genes, including magnetosome genes such as but not limited to MagA,
MamK and MMS16. The ferritin subunits are heavy (HF) and light
subunits (LF) each of which lacks the iron response elements (IRE).
In aspects, the ferritin subunits are mammalian, in aspects
human.
[0009] The co-expression of one or more magnetotactic bacterial
genes, and mammalian iron handling proteins such as modified human
ferritin heavy and light subunits, each lacking iron response
elements (IRE), promotes iron biomineralization and enhances
cellular contrast for molecular imaging using any variety of
techniques such as magnetic resonance imaging (MRI).
[0010] The invention thus provides enhancement and/or regulation of
gene-based, iron contrast by augmenting a cell's iron pool, as for
example stored by a modified form of ferritin, in addition to
increasing iron uptake through for example the MagA transporter or
other magnetotactic bacterial protein(s), including those
associated with forming a magnetosome-like structure. The present
invention addresses current limitations in cell tracking using
exogenously-introduced iron particles, such as superparamagnetic
iron oxide (SPIO) nanoparticles.
[0011] According to an aspect of the present invention is a plasmid
comprising (a) one or more bacterial magnetotactic genes to amplify
iron uptake, compartmentalization and biomineralization in cells in
combination with (b) one or more iron handling proteins that
together augment(s) and/or regulates the cells' iron pool. In
aspects, the iron handling proteins may be of mammalian origin.
[0012] According to another aspect of the present invention is an
expression system comprising one or more magnetotactic genes and
one or more mammalian genes encoding iron handling proteins under
the control of one or more suitable promoters. The one or more
magnetotactic genes may be provided as an operon.
[0013] According to a further aspect of the invention is a double
or triple gene expression system comprising a magnetotactic
bacterial gene and modified human heavy and/or light ferritin
subunits lacking iron response elements (IRE). In aspects, the iron
response element is deleted from the 5' untranslated region of the
human heavy and light ferritin gene. The gene expression system is
provided as a construct for transfection into a variety of
eukaryotic and prokaryotic cell types including mammalian cells,
human or animal as well as bacterial cells. The mammalian cells may
be of any type and are not limited and may include any type of cell
such as stem cells and the like as is understood by one of skill in
the art.
[0014] In aspects the entire iron response element is deleted or a
portion thereof, the portion being sufficient to lack the
expression of the IRE as is understood by one of skill in the
art.
[0015] According to an aspect of the invention is a cell
transfected with a gene construct comprising a magnetotactic
bacterial gene and modified human heavy and/or light ferritin
subunits lacking iron response elements (IRE). In aspects, the
magnetotactic bacterial gene is a MagA gene.
[0016] According to an aspect of the invention is a cell
transfected with a gene construct comprising MagA and modified
human heavy and/or light ferritin subunits lacking iron response
elements (IRE) in the 5' untranslated regions. The cell can be
mammalian or bacterial.
[0017] According to an aspect of the present invention is a dual
expression system where the same promoter element induces
magnetotactic bacterial gene(s), including magnetosome gene(s), and
mammalian genes encoding iron handling proteins. Those skilled in
the art will recognize that this inducible expression may be
engineered to respond to antibiotic stimulation or a specific
cellular transcription factor, as in reporter gene expression. It
is understood that a single cell may be engineered to express
multiple genes.
[0018] According to another aspect of the present invention is the
constitutive expression of one set of genes and inducible
expression of additional gene(s).
[0019] According to a further aspect of the present invention is a
method for making a cell that co-expresses one or more
magnetotactic bacterial genes and mammalian modified ferritin heavy
and light subunits, the method comprising; transfecting a cell with
a construct comprising one or more magnetotactic bacterial genes
and genes encoding modified ferritin heavy and light subunits under
the control of an inducible promoter.
[0020] According to an aspect of the present invention is a method
for making a cell that co-expresses MagA and modified ferritin
heavy and light subunits lacking the IRE (iron responsive element),
the method comprising; transfecting a cell with a construct
comprising MagA and modified ferritin heavy and light subunits
lacking the IRE in the 5' untranslated region of the heavy and
light gene under the control of a suitable inducible promoter.
[0021] According to an aspect of the present invention is the
detection of multiple contrast genes using MRI and MPI imaging
platforms as well as hybrid imaging platforms, such as PET/MRI (4,
11), SPECT/MRI, PET/SPECT/MRI, PET/CT, SPECT/CT, bioluminescence
tomography (BLT)/MRI, BLT/CT, BLT/PET, BLT/PET/MRI (12) and MPI.
Those skilled in the art will recognize that non-invasive imaging
methods and hardware are adaptable to multiple applications.
[0022] According to another aspect of the present invention is the
inducible expression of magnetotactic bacterial gene(s), including
magnetosome gene(s), and mammalian genes encoding iron handling
proteins, like HF and/or LF genes, by two or more distinct
promoters. Thus more than one gene may be monitored at the same
time and the simultaneous expression will provide the maximal or
distinct MR contrast signal.
[0023] A beneficial feature of the present invention is the fact
that the genetically altered cells of the invention can continue to
express and produce magnetosome-like structures and HF and/or LF in
vivo during growth, differentiation and replication of the cell. As
a result, such cells can be visually tracked as they grow,
differentiate and replicate inside a host without dilution of the
genetically-programmed contrast agents. Therefore, these structures
provide long-term in vivo contrast agents in a wide variety of
cells, tissues, organs, etc. With respect to the genetically
altered cells being bacterial cells, these can be transformed in
vitro or ex vivo with the expression systems of the invention and
reintroduced into the gut in order to provide an in vivo contrast
in the gastrointestinal tract.
[0024] The expression systems of the invention may in embodiments
comprise MagA and modified heavy and light ferritin subunits
lacking iron response elements and be used in eukaryotic cells,
such as mammalian cells. The cells may be stem cells or the
construct may be used for transfection into tissues.
[0025] The construct in cells and tissues may be imaged using
magnetic resonance imaging (MRI) or magnetic particle imaging (MPI)
alone or in combination with other imaging modalities, such as
positron emission tomography (e.g., PET/MRI or PET/MPI) or single
photon emission computed tomography (e.g., SPECT/MRI or
SPECT/MPI).
[0026] According to an aspect of the invention there is provided an
expression system for augmenting and/or regulating iron levels in
cells, said expression system comprising (a) one or more bacterial
magnetotactic genes to amplify iron uptake, compartmentalization
and biomineralization in cells, and (b) one or more iron handling
proteins, wherein (a) and (b) are under control of one or more
promoters and, optionally, one or more selection markers.
[0027] According to a further aspect is a mammalian cell
transfected with a plasmid comprising MagA and mammalian ferritin
heavy and light subunit genes lacking the IRE in the 5'
untranslated regions under control of one or more promoters and,
optionally, one or more selection markers.
[0028] According to a further aspect is a method for making a cell
that co-expresses one or more magnetotactic bacterial genes and
modified ferritin heavy and light subunits, the method comprising;
transfecting a cell with a construct comprising one or more
magnetotactic bacterial genes and modified ferritin heavy and light
subunits under the control of an inducible promoter.
[0029] According to a further aspect is method for making a cell
that co-expresses MagA and modified ferritin heavy and light
subunits lacking the IRE, the method comprising; transfecting a
cell with a construct comprising MagA and modified ferritin heavy
and light subunits lacking the IRE in the 5' untranslated region of
the heavy and light genes under the control of a suitable inducible
promoter.
[0030] According to another aspect is a method for producing a
magnetosome-like structure comprising increased amounts of iron
contained therein, the method comprising cultivating a transformed
cell according to any one of claims 22 to 26 under conditions
suitable to effect expression of the genes contained therein.
[0031] According to another aspect is a DNA construct for
expression of multiple gene products in a cell leading to augmented
iron levels, the construct comprising: (a) one or more promoters
located at the 5' end of the construct, which is operable in a
cell, (b) one or more bacterial magnetotactic genes, (c) one or
more mammalian iron handling proteins, and (d) a 3' transcription
termination sequence comprising a polyadenylation signal following
the protein coding sequences.
[0032] Any of the constructs of the invention as described herein
encompass promoters selected from the group consisting of inducible
promoters, constitutive promoters and tissue specific
promoters.
[0033] According to another aspect is a modified breast cancer cell
co-expressing MagA and ferritin heavy and light subunits modified
to lack an iron response element (IRE), wherein said modified
breast cancer cell contains a higher amount of iron than a matched
unmodified breast cancer cell.
[0034] According to a further aspect is a method for detecting
changes in cellular iron, the method comprising co-expressing a
magnetotactic bacterial gene and a eukaryotic iron handling gene in
a cell and monitoring said cell using an imaging method.
[0035] According to a further aspect is a method for tracking
cancer growth and/or metastasis, the method comprising
co-expressing a magnetotactic bacterial gene and a eukaryotic iron
handling gene in a cancer cell and monitoring said cell using an
imaging method.
[0036] According to a further aspect is a method for monitoring
cardiac stem cell transplantation, the method comprising
co-expressing a magnetotactic bacterial gene and a eukaryotic iron
handling gene in a cardiac stem cell and monitoring said cell using
an imaging method.
[0037] According to a further aspect is a method for tracking
neurodegenerative disease, the method comprising co-expressing a
magnetotactic bacterial gene and a eukaryotic iron handling gene in
a neural cell and monitoring said cell using an imaging method.
[0038] According to a further aspect is a method for tracking
internal bacteria, the method comprising co-expressing a
magnetotactic bacterial gene and a eukaryotic iron handling gene in
a bacterial cell and monitoring said cell using an imaging
method.
[0039] According to a further aspect is modified cell co-expressing
one or more magnetosome genes and one or more iron handling genes,
wherein said modified cancer cell contains a higher amount of iron
than a matched unmodified cell.
[0040] The foregoing has broadly outlined the features and
technical advantages of the present invention in order that the
detailed description of the invention that follows may be better
understood. Additional features and advantages of the invention
will be described hereinafter which form the subject of the claims
of the invention. It should be appreciated by those skilled in the
art that the specific embodiment disclosed herein may be readily
utilized as a basis for modifying or designing other structures for
carrying out the same purposes of the present invention. It should
also be realized by those skilled in the art that such equivalent
constructions do not depart from the scope of the invention. The
novel features which are believed to be characteristic of the
invention, both as to its organization and method of operation,
together with further objects and advantages will be better
understood from the following description when considered in
connection with the accompanying figures. It is to be expressly
understood, however, that each of the figures is provided for the
purpose of illustration and description only and is not intended as
a definition of the limits of the present invention.
BRIEF DESCRIPTION OF DRAWINGS
[0041] FIG. 1 shows RT-PCR of MDA-MB-435 cells expressing MagA and
modified ferritin subunits HF+LF. Transcripts were amplified from 1
.mu.g of total RNA, isolated from stably-expressing cells (clone
12), by reverse transcription (RT). The polymerase chain reaction
(PCR) was performed on 4 .mu.l RT, using 60.degree. C. for the
annealing temperature and 35 cycles. Ethidium bromide staining of
complimentary DNA (cDNA) separated on a 1% agarose gel shows the
product amplified with MagA primers (lane 2, 650 bp), HF primers
(lane 3, 450 bp), LF primers (lane 4, 500 bp) and aactin primers
(lane 5, 150 bp). Lane 6 contains an RT negative control for
.alpha.-actin. Lane 1 contains a 1 Kb DNA ladder (Life
Technologies).
[0042] FIG. 2 shows how iron response elements regulate the
expression of ferritin subunits. The iron response element (IRE) is
a hairpin loop structure in the 5' noncoding sequences of the mRNA
of ferritin heavy and light subunits. Under low cellular iron
conditions, when the cell needs to release more iron from storage,
ferritin synthesis is downregulated by the interaction of iron
response protein (IRP) with the IRE. Iron uptake is increased by
stabilizing the synthesis of transferrin receptor mRNA, through
IRP-IRE interactions in the 3' noncoding sequence of the
transferrin receptor transcript. The reverse is true when cellular
iron is high and the cell needs to store more iron and downregulate
iron import (Ponka and Lok (1999) The transferrin receptor: role in
health and disease. Int J Biochem Cell Biol 31, 1111-37).
[0043] The modified ferritin subunits (HF and/or LF) lack the
noncoding regulatory IRE sequences; therefore, this modified form
of ferritin is not subject to control by IRP.
DETAILED DESCRIPTION OF THE INVENTION
[0044] The invention provides for co-expression of (a) one or more
bacterial magnetotactic genes to amplify iron uptake,
compartmentalization and biomineralization in cells, with (b) one
or more genes encoding iron handling proteins that together
augment(s) and/or regulate the cells' iron pool. The invention
provides an improved modified magnetosome that contains more iron
or distinct iron biomineral therein with the combination of the
expressed genes. As a result, mammalian cells or bacterial cells
that are transfected or transformed, respectively, can be more
effectively tracked using various imaging technologies.
[0045] As used herein "a higher amount of iron" may encompass one
or more of a quantified amount, the size of the iron biomineral
produced and the crystal structure of the iron biomineral produced
by the present invention.
[0046] The invention is achieved by way of an expression vector (an
expression construct) that is a plasmid or virus in which the one
or more bacterial magnetotactic genes and the one or more genes
encoding iron handling proteins are introduced into a target cell,
to commandeer the cell's mechanism for protein synthesis to produce
a magnetosome-like structure containing higher levels of iron or a
unique iron biomineral. The plasmid further comprises regulatory
sequences that act as enhancer and promoter regions and lead to
efficient transcription of the gene(s) carried on the expression
vector. The expression vector as described herein will produce a
significant amount of stable messenger RNA, and therefore
proteins.
[0047] The term "gene" will include the use of the gene, functional
fragments thereof or cDNA. One of skill in the art would also
understand that codon optimization may be used with respect to the
genes discussed herein to determine and obtain optimal expression
for a particular cell type whether eukaryotic or bacterial. In
codon optimization an appropropriate DNA sequence is synthesized
specifically to efficiently express the mammalian gene in bacteria
for example by first finding out which codons are the most widely
used in the species of interest, and synthesize a DNA sequence made
up of these. Various commercial programs are available and widely
used for such purpose.
[0048] Suitable magnetotactic bacterial genes for use in the
present invention may be selected from magnetosome genes MagA,
MamK, MMS16 and also those encoded on a magnetosome genomic island
and organized into operons such as the magnetosome membrane operons
MamAB (17 genes including MamA/Mam22, MamB, MamE, MamJ, MamK, MamM,
MamN, MamO, MamP), MamGFDC (4 genes including MamC/Mms13, MamG,
MamD, MamF), MamXY (4 genes), the magnetic particle membrane
specific operon Mms6 (5 genes including Mms6, Mms16, Mms24), the
monocistronic MamW, and genes located outside the magnetosome
genomic island, such as ChpA and those on the magnetotaxis operon
MtxA and the magnetosome membrane operon MmeA (Kolinko, I., LohBe,
A., Borg, S., Raschdorf, O., Jogler, C., Tu, Q., Posfai, M., Tompa,
E., Plitzko, J., Brachmann, A., Wanner, G., Muller, R., Zhang, Y.,
and Schuler, D. (2014) Biosynthesis of magnetic nanostructures in a
foreign organism by transfer of bacterial magnetosome gene
clusters, Nat Nanotechnol 9, 193-197). Combinations of any of these
genes and operons are envisaged in the invention. While bacterial
operons are not normally expressed in mammalian cells, the multiple
genes can be expressed each under control of its own promoter and
selection marker. In this embodiment a single transient
transfection can be done or multiple sequential transfections.
These magnetotactic genes are utilized to amplify iron
biomineralization in cells, in combination with the mammalian genes
such as those encoding ferritin overexpression that is not subject
to regulation by the iron response elements (FIG. 2). These
reporter gene constructs for use in MRI, permit high resolution
molecular imaging and non-invasive, in vivo tracking of cellular
and molecular events.
[0049] Suitable genes encoding iron handling proteins may be
selected from the group consisting of ferritin heavy and light
subunits lacking the IRE and any protein subject to IRE regulation.
Representative proteins include the transferrin receptor (UniProt
P02786), transferrin (Transferrin St. Edward's University. 2005
Jul. 18. Retrieved 2009 Apr. 24; Yang F, Lum J B, McGill J R, Moore
C M, Naylor S L, van Bragt P H, Baldwin W D, Bowman B H (May 1984).
"Human transferrin: cDNA characterization and chromosomal
localization". Proceedings of the National Academy of Sciences of
the United States of America 81 (9): 2752-6.
doi:10.1073/pnas.81.9.2752. PMC 345148. PMID 6585826), Iron
Response Proteins (IRP) 1 and 2 (UniProt P21399; Samaniego F, Chin
J, Iwai K, Rouault T A, Klausner R D (December 1994). Molecular
characterization of a second iron-responsive element-binding
protein, iron regulatory protein 2. Structure, function, and
post-translational regulation". J. Biol. Chem. 269 (49): 30904-10.
PMID 7983023), ferroportin (UniProt Q9NP59 and Q9JH19), DMT1
(UniProt P49281), STEAP3 (UniProt Q658P3) and hepcidin (UniProt
P81172). In aspects of the invention the genes may be mammalian as
is understood by one of skill in the art.
[0050] Ferritin is a protein of 450 kDa consisting of 24 subunits
that is present in every cell type. In vertebrates, these subunits
are both the light (L) (UniProt 02792) and the heavy (H) type
(UniProt P02794) with an apparent molecular weight of 19 kDa or 21
kDa respectively; their sequences are about 50% homologous.
Ferritin genes are highly conserved between species. All vertebrate
ferritin genes have three introns and four exons. The tyrosine
residue at amino acid position 27 in the H subunit is thought to be
associated with biomineralization.
[0051] The expression systems of the present invention can be used
with any type of eukaryotic and prokaryotic cell. One of skill in
the art would understand that the invention is applicable to
eukaryotes in general, birds, plants, fungi, insects, fish, yeast,
amphibians, reptiles, and invertebrates such as insects. In aspects
the eukaryotic cells are mammalian, and may be human or animal.
Mammalian cells may include for example cancer cells, nerve cells,
muscle cells, cardiac cells, epithelial cells, adipocytes and stem
cells. The expression systems of the present invention may also be
used with prokaryotic cells, that is bacterial cells. Bacterial
cells that are native to the gut of mammals can also be transformed
with the expression systems of the present invention. Suitable
bacteria may belong to the genera Bacteroides, Clostridium,
Fusobacterium, Eubacterium, Ruminococcus, Peptococcus,
Peptostreptococcus, Bifidobacterium, Escherichia and Lactobacillus.
In this embodiment, the gastrointestinal tract of a mammal can be
effectively imaged when the transformed bacteria are reintroduced
into a mammal's gut.
[0052] Suitable promoters for use in the present invention are
generally known in the field of molecular biology and may include
inducible promoters, constitutive promoters and tissue specific
promoters as is understood by one of skill in the art. Viral
promoters may be chosen from, for example, cytomegalovirus (CMV;
human immediate early), Rous sarcoma virus (RSV), simian virus 40
(SV40), and the long terminal repeat from Moloney murine leukemia
virus (LTR). Mammalian promoters may be chosen from, for example,
the elongation factor (EF) 1.alpha. promoter, widely useful in
mammalian cells; the cytokeratin 18 (K18) promoter; the cytokeratin
19 (K19) promoter; the tissue kallikrein promoter (Kall); the
amylase promoter (AMY); and rat aquaporin-5 (rAQP5). In addition to
these promoters that provide constitutive expression, the invention
covers the use of more selective promoters that respond to
particular cellular transcription factors, such as the minimal NIS
(sodium iodide symporter) promoter that responds to Nkx2.5 (Dentice
et al. (2004), Mol Cell Biol 24, 7863-7877). The combination of
genes expressed to produce a magnetosome-like structure may be
regulated by different promoters, constitutive or selective.
[0053] The invention as incorporated into plants and plant cells,
one of skill in the art understands that several plant expression
vectors are based on the Ti plasmid of Agrobacterium tumefaciens,
where DNA to be inserted into plant is cloned into the T-DNA, a
stretch of DNA flanked by a 25-bp direct repeat sequence at either
end, and which can integrate into the plant genome. The T-DNA also
contains the selectable marker. The Agrobacterium provides a
mechanism for transformation, integration of into the plant genome,
and the promoters for its vir genes may also be used for the cloned
genes. Plant viruses may be used as vectors when Agrobacterium is
not suitable for use in a specific plant. Examples of plant virus
that can be used are the tobacco mosaic virus (TMV), potato virus
X, and cowpea mosaic virus. The protein may be expressed as a
fusion to the coat protein of the virus and is displayed on the
surface of assembled viral particles, or as an unfused protein that
accumulates within the plant. Expression in plant using plant
vectors is often constitutive, and a commonly used constitutive
promoter in plant expression vectors is the cauliflower mosaic
virus (CaMV) 35S promoter.
[0054] Eukaryotic expression systems employing insect cell hosts
are based upon one of two vector types: plasmid or plasmid-virion
hybrids, the latter being most commonly used. The typical insect
host is the common fruit fly, Drosophila melanogaster, however,
other insect hosts include mosquito (Aedes albopictus), fall army
worm (Spodoptera frugiperda), cabbage looper (Trichoplusia ni),
salt marsh caterpillar (Estigmene acrea) and silkworm (Bombyx mon).
In most all cases, heterologous protein overexpression occurs in
suspension cell cultures. The exception, and one of the advantages
of plasmid-virion systems, is that the recombinant virus may also
be injected into larval host hemocel or literally fed to the mature
host.
[0055] Plasmid-based vector systems provide a mechanism for both
transient and long-term expression of recombinant protein and are
commercially available such as the Drosophila Expression System
(DES) (Invitrogen.TM.). The transfection of competent D.
melanogaster cells with engineered plasmid will mediate the
transient (2-7 days) expression of heterologous protein.
Establishing transformed cells that will express protein for longer
time periods requires that the host cells be cotransfected with a
"selection" vector, resulting in the stable integration of the
expression cassette into the host genome. Constitutive expression
is mediated using the Ac5 Drosophila promoter, whereas a
metallothionein promoter guides copper-inducible expression. The
DES vectors are designed with multiple cloning sites for insertion
of the heterologous protein gene in any of three reading frames. A
choice of vectors also provides for the expression of a variety of
C-terminal fusion tags: V5 epitope for identification of expressed
protein with V5 epitope antibody, polyhistidine peptide for
simplified purification with metal chelate affinity resin, and the
BiP secretion leader peptide.
[0056] To amplify cellular iron storage for the purpose of
biomineralization, in one non-limiting embodiment of the present
invention MagA was overexpressed in combination with a dysregulated
form of ferritin. In the absence of the IRE, ferritin does not
respond to cellular iron binding proteins 1 and 2, thereby
circumventing a key step in iron homeostasis: regulation of iron
storage through receptor-mediated uptake by the interaction of
transferrin, transferrin receptor and ferritin. Hence the absence
of IRE allows greater flexibility in the control of iron levels and
biominerals by magnetotactic bacterial genes.
[0057] The invention provides genetically engineered cells that
produce magnetosome-like structures and HF and/or LF iron storage,
as contrast agents for mapping and/or imaging of organs, tissues,
cells, sub-cellular structures, proteins and peptides in living
organisms both in vivo and in vitro. The method of the invention
genetically alters cells to enhance iron storage in HF and/or LF
and produce magnetosome-like structures as dense core vesicles that
form MR contrast agents in the cell. The invention also provides
genetic constructs from magnetotactic bacterial genes, including
those of the magnetosome, and from mammalian genes, such as HF
and/or LF, that may be expressed from vectors bearing inducible
promoters or encoding other useful genes for targeting cells or for
therapeutic treatments that can be followed by functional imaging
or long-term tracking of transfected cells.
[0058] It is herein demonstrated that the magnetotactic bacterial
gene and putative iron transporter, MagA, enhances MR contrast in
iron-supplemented cells and in tissue formed from transplanted
MagA-expressing cells. The MR contrast has been compared in clonal
lines of MagA expressing cells to those expressing ferritin heavy
and light chains, lacking iron response elements (HF and/or LF).
The transverse relaxation rates, R2' in particular, are sensitive
to cellular iron content. Changes in this MR parameter may be used
to quantify cellular iron and improve the specificity of detection.
The relationship between R2 and inter-echo time is investigated to
improve cellular detection of iron using molecular MRI.
[0059] The present invention demonstrates the triple expression
system/construct of the present invention for use to further
augment MR contrast (FIG. 1, Table 1).
[0060] The invention encompasses various expression strategies for
magnetotactic bacterial, magnetosome and mammalian genes like the
modified ferritin genes. Since each set of genes may provide
contrast in the context of mammalian cell expression, they may
operate independently and in an additive manner. Thus the
possibility of distinct MR signatures are encompassed and within
the scope of the invention for all types of genes and cells
selected.
[0061] The invention has particular use with eukaryotic cells that
express and overexpress one or more magnetotactic bacterial and/or
magnetosome proteins as magnetosome-like structure contrast agents,
in combination with mammalian genes like HF and/or LF for iron
storage, permitting in vivo MRI, MPI, hybrid MR or x-ray imaging
studies to follow the localization, proliferation, and long-term
tracking of iron loaded cells. These cells may be tissue specific
and permit non-invasive in vivo imaging of specific physiological
or molecular functions.
[0062] Imaging systems that can be used with the present invention
include at least the following, which can also be used in
combination: positron emission tomography (PET), magnetic resonance
imaging (MRI), gamma-ray imaging camera (GREI-II), computer
tomography (CT), Single photon emission computed tomography (SPEC),
bioluminescence tomography (BLT) and magnetic particle imaging
(MPI). Magnetic particle imaging (MPI) is a new modality for
imaging distributions of iron oxide nanoparticle tracers in vivo
with good contrast, high sensitivity, and good spatial resolution,
and thus is promising for clinical imaging in angiography and
oncology. MPI requires high-quality iron oxide nanoparticle tracers
with tailored magnetic and surface properties to achieve its full
potential. Thus this technique is suitable for use with the
presently claimed invention.
[0063] The present invention has further wide potential clinical
uses such as, but not limited to, those described below.
Detecting Changes in Cellular Iron
[0064] Mammalian cells change their iron requirements to meet a
given physiological need in both health (13) and disease (14). We
demonstrate that both MagA and HF and/or LF expression respond to
changes in extracellular iron while cellular iron homeostasis, as
measured by changes in the level of transferrin receptor, appears
intact. Expression of MagA and HF and/or LF may be utilized as
sensors of changes in physiological iron levels.
[0065] Using MR detection methods, such as transverse relaxation
rates, changes in cellular iron levels and iron biomineralization
may be measured using a combination of magnetotactic bacterial
genes, such as MagA, including magnetosome genes, and HF and/or LF.
This provides a noninvasive tool for assessing the iron status of a
given cell type.
[0066] The onset of changes in iron uptake or export and monitoring
fluctuations in iron handling may be tracked by expressing a
combination of magnetotactic bacterial genes, like MagA, including
magnetosome genes, and HF and/or LF. Since transverse relaxation
rates are a quantifiable measure of MR contrast and are related to
cellular iron content, fluctuations in cellular iron throughout the
cell's life cycle may be monitored.
[0067] Iron biomineralization may be amplified in mammalian cells,
using a combination of magnetotactic bacterial genes, like MagA,
including magnetosome genes, and HF and/or LF. This amplification
of gene-based iron contrast will improve MR detection of cells
without introducing cytotoxicity or altering endogenous cellular
programming.
[0068] Under circumstances where altering the cell's iron handling
abilities is desirable, a combination of magnetotactic bacterial
genes, like MagA, including magnetosome genes, and HF and/or LF may
be genetically engineered in the cell in order to introduce changes
in iron handling. Such changes may influence the cell's labile iron
pool and iron import, storage and export by creating a
magnetosome-like compartment. Synthesis of a magnetosome-like
structure may be genetically associated with a cellular function,
reflecting an endogenous activity or overexpression of a desired
macromolecule.
[0069] Bacteria harboring a combination of magnetotactic bacterial
genes, like MagA, including magnetosome genes, and HF and/or LF may
interact with mammalian cells and localize to sites within the
body, such as the gut. This interaction may be detected by MRI or
its hybrid modalities and signal the onset of a physiological
process, be it in health or illness. This type of interaction has
been identified as inter-kingdom signalling (15).
Tracking Cancer Growth and Metastasis
[0070] Cancer cells generally consist of a proliferative phenotype;
however, dormant cancer cells may assume a quiescent state until
reactivated by a stimulatory signal. It will be possible to use the
combination of magnetotactic bacterial genes, like MagA, including
magnetosome genes, and HF and/or LF to track the changes in cancer
cell activity.
[0071] a) Many transplanted cancer cells will form tumour
xenografts in animal models (6). A combination of magnetotactic
bacterial genes, like MagA, including magnetosome genes, and HF
and/or LF may be used to monitor tumour growth and metastasis in
tumour xenografts using MRI.
[0072] b) P19 cells are a mouse embryonic carcinoma with stem cell
characteristics and will differentiate into each of the 3 tissue
types: endoderm, mesoderm and ectoderm. Introduction of a
combination of magnetotactic bacterial genes, like MagA, including
magnetosome genes, and HF and/or LF may be used to monitor cancer
cell differentiation by MRI and better understand stem cell
activity (11). Using this method, features of cancer stem cell
activity such as the fraction of cells that differentiate in
response to a given stimulus can be monitored.
[0073] c) Using specific promoters to drive contrast gene
expression, transcription factor activities will be examined that
are important in a given type of cancer. For example, a combination
of magnetotactic bacterial genes, like MagA, including magnetosome
genes, and HF and/or LF may be expressed to monitor Nkx2.5 activity
by reporter gene expression (12). This method will also permit
simultaneous tracking of more than one oncoprotein activity by
using different promoters for each reporter gene involved in
generating MR contrast.
[0074] d) One of the advantages of non-invasive imaging is the
ability to investigate environmental cues of tumour formation
within an in vivo context (16). Expressing a combination of
magnetotactic bacterial genes, like MagA, including magnetosome
genes, and HF and/or LF may be used to examine the context of
tissue-specific tumour growth and metastasis. This method will
combine the superior anatomy of MRI with molecular function and
reveal the similarities and differences in cancer growth among
transformed cell types and target organs.
[0075] e) Combinations of magnetotactic bacterial genes, like MagA,
including magnetosome genes, and HF and/or LF may be expressed in
cells derived from primary tumours to non-invasively track growth
and metastasis of human disease in orthotopic animal models. This
will provide a measure of personalized medicine for developing
therapies and predicting outcomes ahead of, or concurrent to, the
course of human disease.
Cardiac Stem Cell Transplantation
[0076] After a heart attack, the patient is often left with a large
amount of scar tissue in place of normally contracting heart
muscle. If the amount of tissue is large enough, the patient's
physical activity is limited and they may go on to chronic heart
failure and death. Heart transplantation remains the treatment of
choice, but the number of available organs will never meet more
than a small fraction of the growing demand (17, 18). As another
treatment option, stem cell therapy to regenerate the damaged heart
is being aggressively pursued (19). The present invention has use
to image, quantify and monitor the progression of transplanted stem
cells from undifferentiated to differentiated states, as the cells
repopulate the scar tissue with normally functioning heart tissue.
The use of magnetosome-like structures, augmented by increased
ferritin, to track the progress of tissue regeneration has both
research and therapeutic applications.
[0077] a) Prior to transplantation, stem cells may be transfected
with genes that produce magnetosome-like structures and HF and/or
LF genes of the invention to follow the fate of the transplanted
cells by MR imaging. This would follow the original stem cell
population, from transplantation to lineage commitment and
differentiation, by the combination of magnetosome-like structures
and augmented ferritin storage.
[0078] To monitor the switch from proliferation to differentiation,
cells would be transfected with magnetotactic bacterial, including
magnetosome, and HF and/or LF constructs in which the promoter
responds to stage-specific differentiation signals. This will
indicate early and late events in stem cell differentiation and
localize these events within the injured heart.
[0079] b) Different types of cellular differentiation may be
monitored by transfecting stem cells with magnetotactic bacterial,
including magnetosome, and HF and/or LF constructs of the invention
that respond to transcription factors present in specific types of
cardiac cells, such as smooth muscle cells, endothelial cells or
myocytes. This will indicate the number of stem cells needed for
successful treatment and how efficient stem cells are at producing
functional myocardium.
[0080] c) The rate of stem cell loss after transplantation may also
be monitored by placing magnetotactic bacterial, including
magnetosome, and HF and/or LF genes behind promoters sensitive to
cell death signals, including apoptosis, necrosis, autophagy and
cornification (20). Alternatively, magnetotactic bacterial,
including magnetosome, and HF and/or LF genes may be co-expressed
with early markers of cell death. In this context, magnetosome-like
structure formation and augmented ferritin storage protein would
localize the extent of cell death that undermines stem cell therapy
in a given organ.
Tracking Neurodegenerative Disease
[0081] Iron misregulation has been acknowledged in a number of
diseases, including Alzheimer's disease (21). The Amyloid Precursor
Protein (APP) has an IRE in the 5' untranslated region of the mRNA.
The role of biometal dysregulation and oxidative stress in A.beta.
amyloid formation may be detected by the expression of
magnetotactic bacterial, like MagA, including magnetosome, and HF
and/or LF genes in neural cells.
[0082] a) Iron uptake may be monitored by the combination of
magnetotactic bacterial, like MagA, including magnetosome, and HF
and/or LF gene expression, which respond to iron supplementation.
In this example, MagA and HF and/or LF are acting like a sensor of
iron. MRI may be used to detect iron accumulation ahead of the
amyloid plaque. The constructs and methods of the invention may
also reveal the balance of IRE+/IRE- isoforms of key proteins in
health and disease.
[0083] b) Changes in APP expression may be monitored using MRI by
expression of the combination of magnetotactic bacterial genes,
like MagA, including magnetosome, and HF and/or LF genes using
vectors that respond to the APP promoter.
[0084] c) Potentially, therapies will be devised such that MagA and
HF and/or LF remove cytotoxic iron by storing it in a safe form: as
an iron biomineral in modified ferritin and/or a magnetosome-like
structure.
[0085] d) New PET probes have recently been developed to A.beta.
amyloid and tau proteins to enable imaging of the onset and
progression of Alzheimer's disease. This paves the way for PET/MRI
in pre/clinical models of the disease. Magnetotactic bacterial,
including MagA and magnetosome, and HF and/or LF gene expression in
cells, tissues and animals can be now used for the purpose of
PET/MR imaging in this disease.
Using Combinations of Magnetotactic and Mammalian Genes for Cell
Tracking
[0086] The invention relates to the use of magnetotactic bacterial
genes, including magnetosome genes, and mammalian genes, including
the modified ferritin subunits, in combinations that augment or
modulate MR contrast by regulating cellular iron biomineralization
and/or the formation of magnetosome-like structures. These
structures may generate all or part of the magnetosome, including
modifications to iron uptake, iron biomineralization, iron
compartmentalization and the arrangement of magnetosome-like
structures within the cell.
[0087] a) MamJ and MamK are magnetosome proteins needed for the
alignment of magnetosomes into a chain, connected to the
cytoskeleton. Disruption of this interaction removes the chain-like
structure and results in magnetosomes that are either dispersed or
in clusters within the cytoplasm. Since each magnetosome normally
constitutes a single magnetic domain, their arrangement within the
cell will influence the MR contrast signal.
[0088] b) Regulatory proteins such as MamI may be used to dictate
when the magnetosome-like structure will be properly synthesized
(Kolinko, I., LohBe, A., Borg, S., Raschdorf, O., Jogler, C., Tu,
Q., Posfai, M., Tompa, E., Plitzko, J., Brachmann, A., Wanner, G.,
Muller, R., Zhang, Y., and Schuler, D. (2014) Biosynthesis of
magnetic nanostructures in a foreign organism by transfer of
bacterial magnetosome gene clusters, Nat Nanotechnol 9, 193-197).
In this way essential magnetosome genes may be used to regulate
when and where the magnetosome-like structure will be
expressed.
[0089] c) The iron biomineral in magnetosomes is partially
regulated by Mms6. In this way, characteristics of the iron
biomineral may be altered by select gene expression to influence
the MR signal. Such regulation may include the size and composition
of the biomineral, giving hematite, magnetite (Fe.sub.3O.sub.4),
greigite (Fe.sub.3S.sub.4), or another biomineral.
[0090] d) Using select magnetotactic and mammalian genes to impart
distinct magnetic signatures for MRI, changes in cellular activity
may be tracked by expressing different combinations of these genes
at different developmental stages. In this embodiment, the MR
signal from a magnetosome-like structure appears at the onset of
promoter stimulation by a given transcription factor. As that
activity changes so does the MR signal. In addition, as new
activities appear the MR signal may be modified again by
genetically programming a different feature of the magnetosome-like
structure to respond to these subsequent cellular factors. This
strategy may be used to understand the factors that dictate a
disease process, ahead of permanent tissue damage.
Magnetic Particle Imaging of Magnetosome-Like Structures
[0091] Magnetic Particle Imaging (MPI) is an emerging area of MRI
where nanoparticles of iron are non-invasively tracked and
quantified (Saritas, E U, Goodwill, P W, Croft, L R, Konkle, J J,
Lu, K, Zheng, B and Conolly, S M (2013) Magnetic Particle Imaging
(MPI) for NMR and MRI Researchers. J Magn Reson 229, 116-126).
Magnetosome-like structures can be used for MPI where genes from
magnetotactic bacteria are co-expressed with mammalian genes to
create the iron nanoparticles that have specific MPI signals Biomed
Tech (Berl). 2013 December; 58(6):493-507. doi:
10.1515/bmt-2012-0058. Tailoring the magnetic and pharmacokinetic
properties of iron oxide magnetic particle imaging tracers.
Ferguson R M, Khandhar A P, Arami H, Hua L, Hovorka O, Krishnan K
M.
Co-Expression of Human and Magnetotactic Bacterial Genes in
Prokaryotes
[0092] Bacteria that live in the human gut may be genetically
programmed to co-express magnetotactic bacterial genes, including
magnetosome genes, and human genes, like the ferritin heavy and
light subunits, to produce magnetosome-like structures.
[0093] a) In an aspect of the invention, these gut microbes may
secrete therapeutic proteins to treat intestinal diseases and the
magnetosome-like structures they harbour will permit non-invasive
tracking of their location. Since this type of therapy may be
stopped by flushing out the microbes with the use of laxatives, MRI
can be used to verify the removal the magnetic bacteria.
[0094] b) In another aspect of the invention, gut bacteria may be
engineered for production of magnetosome-like structures once a
stimulatory signal is generated by the subject to initiate
formation of the contrast agent in situ. The stimulatory agent may
be endocrine, paracrine or autocrine. Furthermore, the combination
of genes expressed may be programmed to give a unique
magnetosome-like structure that depends on the nature of the
stimulant.
[0095] c) Administration and monitoring of this therapy may be
externally regulated. Gut microbes expressing a combination of
magnetotactic bacterial and human genes to form magnetosome-like
structures may be administered and allowed to migrate to the
desired location in the GI tract, prior to activation of
therapeutic gene expression by an oral antibiotic like
tetracycline. This would ensure that the bacteria have reached the
correct target along the intestine and minimize side effects
elsewhere, such as in the stomach or bowel.
EXAMPLES
RT-PCR of MDA-MB-435 Cells Expressing MagA and Modified Ferritin
Subunits HF+LF (FIG. 1)
[0096] Transcripts were amplified from 1 .mu.g of total RNA,
isolated from stably-expressing cells (clone 12), by reverse
transcription (RT). The polymerase chain reaction (PCR) was
performed on 4 .mu.l RT, using 60.degree. C. for the annealing
temperature and 35 cycles. Ethidium bromide staining of
complimentary DNA (cDNA) separated on a 1% agarose gel shows the
product amplified with MagA primers (lane 2, 650 bp), HF primers
(lane 3, 450 bp), LF primers (lane 4, 500 bp) and .alpha.-actin
primers (lane 5, 150 bp). Lane 6 contains an RT negative control
for .beta.-actin. Lane 1 contains a 1 Kb DNA ladder (Life
Technologies).
TABLE-US-00001 TABLE 1 ICP-MS~ analysis of iron and zinc content in
MDA- MB-435 cells expressing MagA and HF + LF Amount of Amount of
[Protein]* [Fe] Fe/Protein [Zn] Zn/Protein Ratio of Sample (mg/ml)
(.mu.g/ml) (.mu.g/mg) (.mu.g/ml) (.mu.g/mg) Fe/Zn
RIPA/inhibitors.dagger-dbl. 0 0 ND 0 ND ND 1. Cells minus Fe 1.00
0.029 0.029 0.108 0.108 0.273 2. Cells minus Fe 1.00 0.038 0.038
0.112 0.112 0.342 3. Cells plus Fe 1 day 1.00 0.341 0.341 0.115
0.115 2.969 4. Cells plus Fe 3 days 1.00 0.471 0.471 0.123 0.123
3.835 5. Cells plus Fe 5 days 1.00 0.510 0.510 0.085 0.085 5.973
~ICP-MS, Inductively-coupled plasma mass spectrometry {circumflex
over ( )} Stably-expressing cells (clone 12) were cultured in the
presence (plus Fe) and absence (minus Fe) of medium supplemented
with iron: 250 .mu.M ferric nitrate. *Protein was measured by the
BCA assay: Smith et al. (1985) Anal. Biochem. 150, 76-85.
.dagger-dbl.Cells were lysed in RIPA buffer (10 mM Tris-HCl pH
7.5/140 mM NaCl/1% NP-40/1% sodium deoxycholate/0.1% SDS)
containing protease inhibitors (Complete Mini, Roche Diagnostic
Systems).
TABLE-US-00002 TABLE 2 Transverse relaxation rates.sup.a in
MDA-MB-435 cells co-expressing MagA and the modified ferritin
subunits (HF + LF) Sample.sup.b R2* R2 MagA + HF + 13.65 .+-. 0.15
11.74 .+-. 0.64 LF MagA + HF + 14.07 .+-. 0.33 13.20 .+-. 0.50 LF +
Fe .sup.aCells were mounted in spherical gelatin phantoms for
measurement of relaxation rates at 3T following the method of
Sengupta et al, 2014. Results are the average of 2 experiments.
.sup.bStably-expressing cells (clone 12) were cultured in the
presence (+Fe) and absence of medium supplemented with iron: 250
.mu.M ferric nitrate.
REFERENCES
[0097] 1. Komeili, A. (2007) Molecular mechanisms of magnetosome
formation, Annu Rev Biochem 76, 1-27. [0098] 2. Zurkiya, O., Chan,
A. W., and Hu, X. (2008) MagA is sufficient for producing magnetic
nanoparticles in mammalian cells, making it an MRI reporter, Magn
Reson Med 59, 1225-1231. [0099] 3. Benoit, M., Mayer, D., Barak,
Y., Chen, I., Hu, W., Cheng, Z., Wang, S., Spielman, D., Gambhir,
S., and Matin, A. (2009) Visualizing implanted tumors in mice with
magnetic resonance imaging using magnetotactic bacteria, Clin
Cancer Res 15, 5170-5177. [0100] 4. Goldhawk, D., Rohani, R.,
Sengupta, A., Gelman, N., and Prato, F. (2012) Using the
magnetosome to model effective gene-based contrast for magnetic
resonance imaging, WIRES Nanomed Nanobiotechnol Epub ahead of
print, doi: 10.1002/wnan.1165. [0101] 5. Goldhawk, D., Lemaire, C.,
McCreary, C., McGirr, R., Dhanvantari, S., Thompson, R., Figueredo,
R., Koropatnick, J., Foster, P., and Prato, F. (2009) Magnetic
resonance imaging of cells overexpressing MagA, an endogenous
contrast agent for live cell imaging, Mol Imaging 8, 129-139.
[0102] 6. Rohani, R., Figueredo, R., Bureau, Y., Koropatnick, J.,
Foster, P., Thompson, R., Prato, F., and Goldhawk, D. (2013)
Imaging tumor growth non-invasively using expression of MagA or
modified ferritin subunits to augment intracellular contrast for
repetitive MRI, Mol Imaging Biol, Epub ahead of print, doi:
10.1007/s11307-11013-10661-11308. [0103] 7. Anderson, C., Shen, M.,
Eisenstein, R., and Leibold, E. (2012) Mammalian iron metabolism
and its control by iron regulatory proteins, Biochem Biophys Acta
1823, 1468-1483. [0104] 8. Sengupta, A., Quiaoit, K., Thompson, R.,
Prato, F., Gelman, N., and Goldhawk, D. (2013) Biophysical features
of MagA expression in mammalian cells: implications for MRI
contrast, Frontiers in Microbiotechnology, Ecotoxicology and
Bioremediation, submitted [0105] 9. Lee, C., Thompson, R., Prato,
F., Goldhawk, D., and Gelman, N. (2013) Transverse relaxation rate
(R2) dependence on refocusing pulse interval (2tau) in MagA
expressing breast/melanoma tumor cells, In World Molecular Imaging
Conference, Abstract LBAP 129, Savannah, USA. [0106] 10. Sengupta,
A., Rohani, R., Thompson, R., Prato, F., Goldhawk, D., and Gelman,
N. (2012) MRI relaxation rates in tumour cells expressing the MagA
reporter gene In International Society for Magnetic Resonance in
Medicine Scientific Workshop on MRI-based Cell Tracking, Abstract
26, Miami, USA. [0107] 11. Liu, L., McGirr, R., Bondoc, A.,
Thompson, R., Prato, F., Goldhawk, D., and Hoffman, L. (2013)
Non-Invasively Targeting Myocardial Progenitor Cells for the
Treatment of Duchenne Muscular Dystrophy-Related Cardiomyopathy
using MRI/PET, In Stem Cell Network, Abstract accepted, Banff,
Canada. [0108] 12. Quiaoit, K., Koropatnick, J., Gelman, N., and
Goldhawk, D. (2013) MagA Reporter Gene Expression for Magnetic
Resonance Imaging of Breast Carcinoma, In London Health Research
Day, Biomedical Imaging & Engineering Abstract 33, London,
Canada. [0109] 13. Recalcati, S., Locati, M., Marini, A.,
Santambrogio, P., Zaninotto, F., De Pizzol, M., Zammataro, L.,
Girelli, D., and Cairo, G. (2010) Differential regulation of iron
homeostasis during human macrophage polarized activation, Eur J
Immunol 40, 824-835. [0110] 14. Pantopoulos, K., Porwal, S.,
Tartakoff, A., and Devireddy, L. (2012) Mechanisms of mammalian
iron homeostasis, Biochemistry 51, 5705-5724. [0111] 15. Braun, R.
(2013) When harmless bacteria go bad, Scienfific American. [0112]
16. Ghajar, C., Peinado, H., Mori, H., Matei, I., Evason, K.,
Brazier, H., Almeida, D., Koller, A., Najjar, K., Stainier, D.,
Chen, E., Lyden, D., and Bissell, M. (2013) The perivascular niche
regulates breast tumour dormancy, Nat Cell Biol 15, 807-817. [0113]
17. IHME, and Cohen, J. (2012) Health metrics. A controversial
close-up of humanity's health, Science 338, 1414-1416. [0114] 18.
News. (2013) World Disease by the Numbers, Science 341, 325. [0115]
19. Makkar, R., Smith, R., Cheng, K., Malliaras, K., Thomson, L.,
Berman, D., Czer, L., Marban, L., Mendizabal, A., Johnston, P.,
Russell, S., Schuleri, K., Lardo, A., Gerstenblith, G., and Marban,
E. (2012) Intracoronary cardiosphere-derived cells for heart
regeneration after myocardial infarction (CADUCEUS): a prospective,
randomised phase 1 trial, Lancet 379, 895-904. [0116] 20. Kroemer,
G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E.,
Baehrecke, E., Blagosklonny, M., EI-Deiry, W., Golstein, P., Green,
D., Hengartner, M., Knight, R., Kumar, S., Lipton, S., Malorni, W.,
Nunez, G., Peter, M., Tschopp, J., Yuan, J., Piacentini, M.,
Zhivotovsky, B., and Melino, G. (2009) Classification of cell
death: recommendations of the Nomenclature Committee on Cell Death
2009, Cell Death Differ 16, 3-11. [0117] 21. Huang, X., Moir, R.,
Tanzi, R., Bush, A., and Rogers, J. (2004) Redox-active metals,
oxidative stress, and Alzheimer's disease pathology, Ann NY Acad
Sci 1012, 153-163. [0118] 22. Ferguson R M, Khandhar A P, Arami H,
Hua L, Hovorka O, Krishnan K M. Biomed Tech (Berl). 2013 December;
58(6):493-507. doi: 10.1515/bmt-2012-0058. Tailoring the magnetic
and pharmacokinetic properties of iron oxide magnetic particle
imaging tracers.
[0119] Although the present invention and its advantages have been
described in detail, it should be understood that various changes,
substitutions and alterations can be made herein without departing
from the scope of the invention as defined by the appended claims.
Moreover, the scope of the present application is not intended to
be limited to the particular embodiments of the process,
composition of matter, means, methods and steps described in the
specification.
* * * * *